1921
Volume 96, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The safety and immunogenicity of four formulations of an investigational tetravalent dengue purified inactivated vaccine (DPIV), formulated at 1 or 4 μg with aluminum hydroxide (alum) or at 1 μg with an adjuvant system (AS01 or AS03), were evaluated in a first-time-in-human, placebo-controlled, randomized, observer-blind, phase 1 trial in the continental United States. Two doses of vaccine or placebo were administered intramuscularly 4 weeks apart to 100 healthy adults 18–39 years of age, randomized 1:1:1:1:1 to receive one of four DPIV formulations or saline placebo. The response to a third dose was evaluated in a subset of nine participants remote from primary vaccination. Humoral immunogenicity was assessed using a 50% microneutralization assay. All DPIV formulations were well tolerated. No vaccine-related serious adverse events were observed through 12 months after the second vaccine dose. In all DPIV groups, geometric mean antibody titers peaked at Day 56, waned through 6 months after the second vaccine dose, and then stabilized. In the nine subjects where boosting was evaluated, a strong anamnestic response was observed. These results support continuation of the clinical development of this dengue vaccine candidate (clinicaltrials.gov: NCT01666652).

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.16-0634
2017-06-07
2017-06-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/96/6/1325.html?itemId=/content/journals/10.4269/ajtmh.16-0634&mimeType=html&fmt=ahah

References

  1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI, , 2013. The global distribution and burden of dengue. Nature 496: 504507.[Crossref]
  2. World Health Organization, 2009. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control, new edition. Geneva, Switzerland: World Health Organization.
  3. Murrell S, Wu SC, Butler M, , 2011. Review of dengue virus and the development of a vaccine. Biotechnol Adv 29: 239247.[Crossref]
  4. Yauch LE, Shresta S, , 2014. Dengue virus vaccine development. Adv Virus Res 88: 315372.[Crossref]
  5. Screaton G, Mongkolsapaya J, Yacoub S, Roberts C, , 2015. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 15: 745759.[Crossref]
  6. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J, , 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 15591567.[Crossref]
  7. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, , 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384: 13581365.[Crossref]
  8. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, , 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372: 113123.[Crossref]
  9. Ishikawa T, Yamanaka A, Konishi E, , 2014. A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available. Vaccine 32: 13261337.[Crossref]
  10. Fernandez S, Thomas SJ, De La Barrera R, Im-Erbsin R, Jarman RG, Baras B, Toussaint JF, Mossman S, Innis BL, Schmidt A, Malice MP, Festraets P, Warter L, Putnak JR, Eckels KH, , 2015. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg 92: 698708.[Crossref]
  11. Martinez LJ, Lin L, Blaylock JM, Lyons AG, Bauer KM, De La Barrera R, Simmons M, Jarman RG, Currier JR, Friberg H, Danko JR, Teneza-Mora NC, Putnak JR, Eckels KH, Thomas SJ, , 2015. Safety and immunogenicity of a dengue virus serotype-1 purified inactivated vaccine: results of a phase 1 clinical trial. Am J Trop Med Hyg 93: 454460.[Crossref]
  12. Simmons M, Burgess T, Lynch J, Putnak R, , 2010. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396: 280288.[Crossref]
  13. Fernandez S, Cisney ED, Tikhonov AP, Schweitzer B, Putnak RJ, Simmons M, Ulrich RG, , 2011. Antibody recognition of the dengue virus proteome and implications for development of vaccines. Clin Vaccine Immunol 18: 523532.[Crossref]
  14. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), 2012. Medical Dictionary for Regulatory Activities (MedDRA), Version 15.0. Available at: http://www.meddra.org. Accessed June 2015.
  15. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL, , 2013. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 88: 7388.[Crossref]
  16. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP, Jr, 2008. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 78: 426433.
  17. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM, , 2010. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28: 17401745.[Crossref]
  18. Leroux-Roels I, Forgus S, De Boever F, Clement F, Demoitie MA, Mettens P, Moris P, Ledent E, Leroux-Roels G, Ofori-Anyinam O, , 2013. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31: 21962206.[Crossref]
  19. George SL, Wong MA, Dube TJ, Boroughs KL, Stovall JL, Luy BE, Haller AA, Osorio JE, Eggemeyer LM, Irby-Moore S, Frey SE, Huang CY, Stinchcomb DT, , 2015. Safety and immunogenicity of a live attenuated tetravalent dengue vaccine candidate in flavivirus-naive adults: a randomized, double-blind phase I clinical trial. J Infect Dis 212: 10321041.[Crossref]
  20. Dayan GH, Galan-Herrera JF, Forrat R, Zambrano B, Bouckenooghe A, Harenberg A, Guy B, Lang J, , 2014. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naive adults in Mexico. Hum Vaccin Immunother 10: 28532863.[Crossref]
  21. Dorigatti I, Aguas R, Donnelly CA, Guy B, Coudeville L, Jackson N, Saville M, Ferguson NM, , 2015. Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and south east Asia. Vaccine 33: 37463751.[Crossref]
  22. Diaz C, Martinez LJ, Eckels KH, Lin L, Campos M, Jarman RG, Barrera RDL, Lepine E, Collard A, Innis BL, Febo I, Thomas SJ, Schmidt AC, , 2015. Phase 1 Study of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine (DPIV): Safety and Immunogenicity Data in Healthy Adults from Puerto Rico through Month 13. 64th ASTMH Annual Meeting, October 25–29, 2015, Philadelphia, PA.
  23. Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS, , 2011. Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine 29: 26072612.[Crossref]
  24. Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O, , 2009. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur adults. Vaccine 27: 853856.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.16-0634
Loading
/content/journals/10.4269/ajtmh.16-0634
Loading

Data & Media loading...

  • Received : 02 Aug 2016
  • Accepted : 17 Jan 2017

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error